SLAM
WST icon

Swiss Life Asset Management’s West Pharmaceutical WST Stock Holding History

Swiss Life Asset Management’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.4M Buy
31,799
+10,131
+47% +$3.1M 0.05% 290
2026
Q1 		$5.43M Buy
21,668
+369
+2% +$91.8K 0.03% 402
2025
Q4 		$5.86M Buy
21,299
+1,811
+9% +$495K 0.03% 375
2025
Q3 		$5.11M Buy
19,488
+2,306
+13% +$560K 0.03% 393
2025
Q2 		$3.76M Buy
17,182
+6,035
+54% +$1.29M 0.02% 440
2025
Q1 		$2.5M Buy
11,147
+1,276
+13% +$352K 0.02% 455
2024
Q4 		$3.23M Buy
9,871
+5,254
+114% +$1.65M 0.02% 391
2024
Q3 		$1.38M Sell
4,617
-562
-11% -$172K 0.02% 429
2024
Q2 		$1.71M Buy
5,179
+182
+4% +$64.3K 0.02% 397
2024
Q1 		$1.98M Sell
4,997
-27,888
-85% -$10.3M 0.03% 339
2023
Q4 		$11.6M Buy
32,885
+4,867
+17% +$1.72M 0.14% 169
2023
Q3 		$10.5M Buy
28,018
+7,147
+34% +$2.76M 0.16% 148
2023
Q2 		$7.98M Buy
20,871
+3,107
+17% +$1.11M 0.12% 221
2023
Q1 		$6.16M Buy
17,764
+531
+3% +$155K 0.09% 274
2022
Q4 		$4.06M Sell
17,233
-5,457
-24% -$1.29M 0.07% 304
2022
Q3 		$5.58M Sell
22,690
-12,693
-36% -$3.87M 0.1% 233
2022
Q2 		$10.7M Buy
35,383
+18,064
+104% +$5.88M 0.17% 141
2022
Q1 		$7.11M Sell
17,319
-1,004
-5% -$393K 0.1% 224
2021
Q4 		$8.59M Buy
18,323
+751
+4% +$323K 0.11% 213
2021
Q3 		$7.46M Buy
17,572
+3,742
+27% +$1.58M 0.1% 230
2021
Q2 		$4.97M Sell
13,830
-1,150
-8% -$380K 0.05% 325
2021
Q1 		$4.22M Sell
14,980
-2,599
-15% -$744K 0.06% 340
2020
Q4 		$4.98M Buy
17,579
+14,824
+538% +$4.16M 0.07% 294
2020
Q3 		$757K Sell
2,755
-7,672
-74% -$2.03M 0.01% 387
2020
Q2 		$2.37M Buy
+10,427
New +$2.05M 0.04% 302
2020
Q1 		– Sell
-3,870
Closed -$582K – 522
2019
Q4 		$582K Buy
+3,870
New +$563K 0.01% 434

Other funds holding WST

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $10.3B AUM 4.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
ProShare Advisors
ProShare Advisors Bethesda, Maryland $69.2B AUM 41.24% 1-Year Est. Return

Swiss Life Asset Management's WST Position: Q2 2026 in Review

Swiss Life Asset Management increased its West Pharmaceutical (WST) stake by 47% in Q2 2026, buying an estimated $3.1M and bringing the position to 31,799 shares worth $11.4M. The position accounts for 0.05% of the portfolio, ranked #290.

Swiss Life Asset Management first reported a position in WST in Q4 2019 and has held it in 26 quarters since. The position peaked at $11.6M in Q4 2023. 565 funds tracked by Wall St. Rank hold WST as of Q2 2026.

  • Swiss Life Asset Management held 31,799 shares of West Pharmaceutical worth $11.4M as of Q2 2026.
  • Swiss Life Asset Management bought 10,131 West Pharmaceutical shares in Q2 2026, an estimated $3.1M.
  • West Pharmaceutical made up 0.05% of Swiss Life Asset Management's portfolio in Q2 2026, its #290 holding.
  • Swiss Life Asset Management first reported a position in West Pharmaceutical in Q4 2019 and has held it in 26 quarters since.
  • Swiss Life Asset Management's West Pharmaceutical position peaked at $11.6M in Q4 2023.
  • 565 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2026.

Based on Swiss Life Asset Management's 13F filing for Q2 2026, filed 29 Jul 2026.